Acrivon Therapeutics Statistics
Total Valuation
ACRV has a market cap or net worth of $243.13 million. The enterprise value is $71.77 million.
Important Dates
The next estimated earnings date is Monday, November 11, 2024, before market open.
| Earnings Date | Nov 11, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ACRV has 30.97 million shares outstanding. The number of shares has increased by 81.46% in one year.
| Shares Outstanding | 30.97M |
| Shares Change (YoY) | +81.46% |
| Shares Change (QoQ) | +59.94% |
| Owned by Insiders (%) | 5.83% |
| Owned by Institutions (%) | 30.27% |
| Float | 11.22M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.15 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 16.16, with a Debt / Equity ratio of 0.02.
| Current Ratio | 16.16 |
| Quick Ratio | 16.00 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -37.78% and return on invested capital (ROIC) is -25.50%.
| Return on Equity (ROE) | -37.78% |
| Return on Assets (ROA) | -24.41% |
| Return on Capital (ROIC) | -25.50% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.13M |
| Employee Count | 61 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +36.52% in the last 52 weeks. The beta is 0.68, so ACRV's price volatility has been lower than the market average.
| Beta (5Y) | 0.68 |
| 52-Week Price Change | +36.52% |
| 50-Day Moving Average | 7.93 |
| 200-Day Moving Average | 7.13 |
| Relative Strength Index (RSI) | 50.21 |
| Average Volume (20 Days) | 60,089 |
Short Selling Information
The latest short interest is 1.11 million, so 3.59% of the outstanding shares have been sold short.
| Short Interest | 1.11M |
| Short Previous Month | 1.21M |
| Short % of Shares Out | 3.59% |
| Short % of Float | 9.91% |
| Short Ratio (days to cover) | 7.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -76.30M |
| Pretax Income | -64.12M |
| Net Income | -69.00M |
| EBITDA | -75.56M |
| EBIT | -76.30M |
| Earnings Per Share (EPS) | -$2.68 |
Full Income StatementBalance Sheet
The company has $180.54 million in cash and $4.22 million in debt, giving a net cash position of $176.32 million or $5.69 per share.
| Cash & Cash Equivalents | 180.54M |
| Total Debt | 4.22M |
| Net Cash | 176.32M |
| Net Cash Per Share | $5.69 |
| Equity (Book Value) | 216.06M |
| Book Value Per Share | 6.98 |
| Working Capital | 171.07M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$53.16 million and capital expenditures -$2.10 million, giving a free cash flow of -$55.26 million.
| Operating Cash Flow | -53.16M |
| Capital Expenditures | -2.10M |
| Free Cash Flow | -55.26M |
| FCF Per Share | -$1.78 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |